Growth in Thanatophoric Dysplasia



Skeletal dysplasias are a complex group of disorders that are characterized by generalized abnormalities of the development of the skeletal growth. The majority of them result from a mutated gene. The bony presentation is characterized by abnormal growth of the limbs, absence of a limb, duplication of fingers or toes, or many other different bone abnormalities. They occur in approximately 1 in 4,000 births and the mode of inheritance is variable, either sporadic (not inherited) or hereditary (recessive or dominant). The understanding of these dysplasias can guide the family for a better genetic council in pregnancy and in future family planning. Thanatophoric dysplasia (TD) is the most common of the lethal skeletal dysplasias, caused by different mutations of fibroblast growth factor receptor 3 (FGFR3) gene. It is one of the short-limb dysplasia and has been classified into two different types, type I and type II, that have a diverse range of phenotypes and genotypes, with the most common difference being the presence of cloverleaf skull in TD type II. Early diagnosis, ideally in utero, is critical because the condition leads to death in utero or shortly after birth. The purpose of this review is to describe the clinical, radiologic, pathologic, and molecular features of TD and newer advances in the different fields that involve this entity.


Skeletal Dysplasia Acanthosis Nigricans Nuchal Translucency Fibroblast Growth Factor Signaling Fibroblast Growth Factor Family 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Fibroblast growth factor


Fibroblast growth factor (FGF) receptor 3 gene


Magnetic resonance imaging


Platyspondylic lethal skeletal dysplasia


Platyspondylic lethal skeletal dysplasia, San Diego type


Platyspondylic lethal skeletal dysplasia, Torrance type

SADDAN dysplasia

Severe achondroplasia with developmental delay and acanthosis nigricans


Thanatophoric dysplasia


Thanatophoric dysplasia type I


Thanatophoric dysplasia type II



We would like to thank Dr. Patrick Shanon for the postmortem brain images, Department of Pathology, Mount Sinai Hospital Toronto, Canada


  1. Baker KM, Olson DS, Harding CO, Pauli RM. Long-term survival in typical thanatophoric dysplasia type 1. Am J Med Genet. 1997;70:427–36.PubMedCrossRefGoogle Scholar
  2. Bonaventure J, Horne WC, Baron R. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor. FEBS J. 2007;274:3078–93.PubMedCrossRefGoogle Scholar
  3. Brodie SG, Kitoh H, Lipson M, Sifry-Platt M, Wilcox WR. Thanatophoric dysplasia type I with syndactyly. Am J Med Genet. 1998;80:260–2.PubMedCrossRefGoogle Scholar
  4. Brodie SG, Kitoh H, Lachman RS, Nolasco LM, Mekikian PB, Wilcox WR. Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations. Am J Med Genet. 1999;84:476–80.PubMedCrossRefGoogle Scholar
  5. Chen CP, Chern SR, Shih JC, Wang W, Yeh LF, Chang TY, Tzen CY. Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia. Prenat Diagn. 2001;21:89–95.PubMedCrossRefGoogle Scholar
  6. Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science. 2002;297:365–9.PubMedCrossRefGoogle Scholar
  7. Coulter CL, Leech RW, Brumback RA, Schaefer GB. Cerebral abnormalities in thanatophoric dysplasia. Childs Nerv Syst. 1991;7:21–6.PubMedCrossRefGoogle Scholar
  8. De Biasio P, Ichim IB, Scarso E, Baldi M, Barban A, Venturini PL. Thanatophoric dysplasia type I presenting with increased nuchal translucency in the first trimester. Prenat Diagn. 2005;25:426–8.PubMedCrossRefGoogle Scholar
  9. Dennis JP, Rosenberg HS, Alvord EC Jr. Megalencephaly, internal hydrocephalus and other neurological aspects of achondroplasia. Brain. 1961;84:427–45.PubMedCrossRefGoogle Scholar
  10. Ford-Perriss M, Abud H, Murphy M. Fibroblast growth factors in the developing central nervous system. Clin Exp Pharmacol Physiol. 2001;28:493–503.PubMedCrossRefGoogle Scholar
  11. Gaffney G, Manning N, Boyd PA, Rai V, Gould S, Chamberlain P. Prenatal sonographic diagnosis of skeletal dysplasias–a report of the diagnostic and prognostic accuracy in 35 cases. Prenat Diagn. 1998;18:357–62.PubMedCrossRefGoogle Scholar
  12. Goncalves L, Jeanty P. Fetal biometry of skeletal dysplasias: a multicentric study. J Ultrasound Med. 1994;13:767–75.PubMedGoogle Scholar
  13. Goutieres F, Aicardi J, Farkas-Bargeton E. A particular cerebral malformation associated with thanatophoric dwarfism. Presse Med. 1971;79:960.PubMedGoogle Scholar
  14. Hevner RF. The cerebral cortex malformation in thanatophoric dysplasia: neuropathology and pathogenesis. Acta Neuropathol. 2005;110:208–21.PubMedCrossRefGoogle Scholar
  15. Inglis-Broadgate SL, Thomson RE, Pellicano F, Tartaglia MA, Pontikis CC, Cooper JD, Iwata T. FGFR3 regulates brain size by controlling progenitor cell proliferation and apoptosis during embryonic development. Dev Biol. 2005;279:73–85.PubMedCrossRefGoogle Scholar
  16. Iwata T, Chen L, Li C, Ovchinnikov DA, Behringer RR, Francomano CA, Deng CX. A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum Mol Genet. 2000;9:1603–13.PubMedCrossRefGoogle Scholar
  17. Kitoh H, Lachman RS, Brodie SG, Mekikian PB, Rimoin DL, Wilcox WR. Extra pelvic ossification centers in thanatophoric dysplasia and platyspondylic lethal skeletal dysplasia-San Diego type. Pediatr Radiol. 1998;28:759–63.PubMedCrossRefGoogle Scholar
  18. Langer LO Jr, Yang SS, Hall JG, Sommer A, Kottamasu SR, Golabi M, Krassikoff N. Thanatophoric dysplasia and cloverleaf skull. Am J Med Genet Suppl. 1987;3:167–79.PubMedCrossRefGoogle Scholar
  19. Lin T, Sandusky SB, Xue H, Fishbein KW, Spencer RG, Rao MS, Francomano CA. A central nervous system specific mouse model for thanatophoric dysplasia type II. Hum Mol Genet. 2003;12:2863–71.PubMedCrossRefGoogle Scholar
  20. Macken MB, Grantmyre EB, Rimoin DL, Lachman RS. Normal sonographic appearance of a thanatophoric dwarf variant fetus at 13 weeks gestation. AJR Am J Roentgenol. 1991;156:149–50.PubMedGoogle Scholar
  21. Maroteaux P, Lamy M, Robert JM. Thanatophoric dwarfism. Presse Med. 1967;75:2519–24.PubMedGoogle Scholar
  22. Miller E, Blaser S, Shannon P, Widjaja E. Brain and bone abnormalities of thanatophoric dwarfism. AJR Am J Roentgenol. 2009;192:48–51.PubMedCrossRefGoogle Scholar
  23. Norman AM, Rimmer S, Landy S, Donnai D. Thanatophoric dysplasia of the straight-bone type (type 2). Clin Dysmorphol. 1992;1:115–20.PubMedGoogle Scholar
  24. Passos-Bueno MR, Wilcox WR, Jabs EW, Sertie AL, Alonso LG, Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat. 1999;14:115–25.PubMedCrossRefGoogle Scholar
  25. Sawai H, Komori S, Ida A, Henmi T, Bessho T, Koyama K. Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results. Prenat Diagn. 1999;19:21–4.PubMedCrossRefGoogle Scholar
  26. Schramm T, Gloning KP, Minderer S, Daumer-Haas C, Hortnagel K, Nerlich A, Tutschek B. Prenatal sonographic diagnosis of skeletal dysplasias. Ultrasound Obstet Gynecol. 2009;34:160–70.PubMedCrossRefGoogle Scholar
  27. Shin DM, Korada S, Raballo R, Shashikant CS, Simeone A, Taylor JR, Vaccarino F. Loss of glutamatergic pyramidal neurons in frontal and temporal cortex resulting from attenuation of FGFR1 signaling is associated with spontaneous hyperactivity in mice. J Neurosci. 2004;24:2247–58.PubMedCrossRefGoogle Scholar
  28. Superti-Furga A, Unger S. Nosology and classification of genetic skeletal disorders: 2006 revision. Am J Med Genet A. 2007;143:1–18.PubMedGoogle Scholar
  29. Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, Wilcox WR, Rimoin DL, Cohn DH, Wasmuth JJ. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet. 1995;9:321–8.PubMedCrossRefGoogle Scholar
  30. Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, Wasmuth JJ, Donoghue DJ, Thompson LM, Francomano CA. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet. 1999;64:722–31.PubMedCrossRefGoogle Scholar
  31. Thomson RE, Pellicano F, Iwata T. Fibroblast growth factor receptor 3 kinase domain mutation increases cortical progenitor proliferation via mitogen-activated protein kinase activation. J Neurochem. 2007;100:1565–78.PubMedGoogle Scholar
  32. Waller DK, Correa A, Vo TM, Wang Y, Hobbs C, Langlois PH, Pearson K, Romitti PA, Shaw GM, Hecht JT. The population-based prevalence of achondroplasia and thanatophoric dysplasia in selected regions of the US. Am J Med Genet A. 2008;146A:2385–9.PubMedCrossRefGoogle Scholar
  33. Weber M, Johannisson T, Thomsen M, Rehder H, Niethard FU. Thanatophoric dysplasia type I: new radiologic, morphologic, and histologic aspects toward the exact definition of the disorder. J Pediatr Orthop B. 1998;7:1–9.PubMedCrossRefGoogle Scholar
  34. Wilcox WR, Tavormina PL, Krakow D, Kitoh H, Lachman RS, Wasmuth JJ, Thompson LM, Rimoin DL. Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. Am J Med Genet. 1998;78:274–81.PubMedCrossRefGoogle Scholar
  35. Zankl A, Neumann L, Ignatius J, Nikkels P, Schrander-Stumpel C, Mortier G, Omran H, Wright M, Hilbert K, Bonafe L, Spranger J, Zabel B, Superti-Furga A. Dominant negative mutations in the C-propeptide of COL2A1 cause platyspondylic lethal skeletal dysplasia, torrance type, and define a novel subfamily within the type 2 collagenopathies. Am J Med Genet A. 2005;133A:61–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Diagnostic ImagingChildren’s Hospital of Eastern Ontario (CHEO)OttawaCanada
  2. 2.Department of Diagnostic ImagingThe Hospital for Sick ChildrenTorontoCanada

Personalised recommendations